Myeloid-derived suppressor cells (MDSCs) are a heterogenic population of immature
myeloid cells with immunosuppressive effects, which undergo massive expansion during …

The success of atezolizumab plus bevacizumab treatment contributed to a shift in systemic
therapies for hepatocellular carcinoma (HCC) towards combinations that include cancer …

Tumour-promoting inflammation is considered one of the enabling characteristics of cancer
development. Chronic inflammatory disease increases the risk of some cancers, and strong …

Tumor recurrence years after seemingly successful treatment of primary tumors is one of the
major causes of mortality in patients with cancer. Reactivation of dormant tumor cells is …

Inflammation is a recognised hallmark of cancer that substantially contributes to the
development and progression of malignancies. In established cancers, there is increasing …

The aim of this evaluation was to identify the first indicators of efficacy for 225Ac-labeled
prostate-specific membrane antigen (PSMA)–617 therapy in a retrospectively analyzed …

In humans, the S100 protein family is composed of 21 members that exhibit a high degree of
structural similarity, but are not functionally interchangeable. This family of proteins …

Prostate cancer (PC) is the most common cancer in men and the second leading cause of
cancer-related death worldwide. Many therapeutic advances over the last two decades have …

Risk of cancer especially of colon, breast, and pancreas is high in diabetic and obese
patients, with potential involvement of augmented expression of RAGE (receptor for …

Immunotherapies like the adoptive transfer of gene-engineered T cells and immune
checkpoint inhibitors are novel therapeutic modalities for advanced cancers. However, some …